Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$25.85−0.56 (-2.12%)
Close on Nov 17, 2026Market cap $12.92BP/E –Yield –
Elanco Animal Health r&d expenses
Research and development expenses are spending on new products and technology.
Elanco Animal Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $371.00M, up 4.8% year over year. For fiscal 2025 it was $368.00M, up 7.0% from the year before. The highest annual figure on record is $369.00M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.00M | +7.0% |
| FY2024 | Dec 31, 2024 | $344.00M | +5.2% |
| FY2023 | Dec 31, 2023 | $327.00M | +1.9% |
| FY2022 | Dec 31, 2022 | $321.00M | -13.0% |
| FY2021 | Dec 31, 2021 | $369.00M | +12.2% |
| FY2020 | Dec 31, 2020 | $329.00M | +21.9% |
| FY2019 | Dec 31, 2019 | $270.00M | +9.5% |
| FY2018 | Dec 31, 2018 | $246.60M | -2.0% |
| FY2017 | Dec 31, 2017 | $251.70M | -5.3% |
| FY2016 | Dec 31, 2016 | $265.80M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $92.00M | 0.0% |
| Q1 FY2026 | Mar 31, 2026 | $97.00M | +3.2% |
| Q4 FY2025 | Dec 31, 2025 | $93.00M | +14.8% |
| Q3 FY2025 | Sep 30, 2025 | $89.00M | +2.3% |
| Q2 FY2025 | Jun 30, 2025 | $92.00M | +3.4% |
| Q1 FY2025 | Mar 31, 2025 | $94.00M | +8.0% |
| Q4 FY2024 | Dec 31, 2024 | $81.00M | +2.5% |
| Q3 FY2024 | Sep 30, 2024 | $87.00M | +1.2% |
| Q2 FY2024 | Jun 30, 2024 | $89.00M | +9.9% |
| Q1 FY2024 | Mar 31, 2024 | $87.00M | +7.4% |
| Q4 FY2023 | Dec 31, 2023 | $79.00M | -1.2% |
| Q3 FY2023 | Sep 30, 2023 | $86.00M | +10.3% |
| Q2 FY2023 | Jun 30, 2023 | $81.00M | -1.2% |
| Q1 FY2023 | Mar 31, 2023 | $81.00M | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $80.00M | -13.0% |
| Q3 FY2022 | Sep 30, 2022 | $78.00M | -17.0% |
| Q2 FY2022 | Jun 30, 2022 | $82.00M | -12.8% |
| Q1 FY2022 | Mar 31, 2022 | $81.00M | -9.0% |
| Q4 FY2021 | Dec 31, 2021 | $92.00M | -20.0% |
| Q3 FY2021 | Sep 30, 2021 | $94.00M | +6.8% |
| Q2 FY2021 | Jun 30, 2021 | $94.00M | +59.3% |
| Q1 FY2021 | Mar 31, 2021 | $89.00M | +32.8% |
| Q4 FY2020 | Dec 31, 2020 | $115.00M | +71.1% |
| Q3 FY2020 | Sep 30, 2020 | $88.00M | +25.9% |
| Q2 FY2020 | Jun 30, 2020 | $59.00M | -14.2% |
| Q1 FY2020 | Mar 31, 2020 | $67.00M | +4.5% |
| Q4 FY2019 | Dec 31, 2019 | $67.20M | +10.0% |
| Q3 FY2019 | Sep 30, 2019 | $69.90M | +18.7% |
| Q2 FY2019 | Jun 30, 2019 | $68.80M | +12.1% |
| Q1 FY2019 | Mar 31, 2019 | $64.10M | -1.7% |
| Q4 FY2018 | Dec 31, 2018 | $61.10M | -1.5% |
| Q3 FY2018 | Sep 30, 2018 | $58.90M | -4.8% |
| Q2 FY2018 | Jun 30, 2018 | $61.40M | – |
| Q1 FY2018 | Mar 31, 2018 | $65.20M | – |
| Q4 FY2017 | Dec 31, 2017 | $62.00M | – |
| Q3 FY2017 | Sep 30, 2017 | $61.90M | – |
See a number that looks wrong?